Dajia Weikang: Continuously optimistic about traditional Chinese medicine new drugs and innovative drugs, closely monitoring and exploring the feasibility of layout.

Dajiaweikang stated on the interactive platform that its subsidiary Tianji Caotang is currently in the process of technical review for the research product Sha Kubaxu Shatansodium tablets, while preparations are being made to apply for the approval of Abam Atorvastatin calcium tablets. The company continues to have high expectations for the development potential and market prospects of traditional Chinese medicine new drugs and innovative drugs, closely monitoring and exploring the feasibility of layout, and improving the industrial chain layout.